Immune checkpoint inhibitor-induced inflammatory arthritis: identification and management
Author:
Affiliation:
1. National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, USA
2. Department of Medicine, MedStar Health Internal Medicine Residency Program, Baltimore, MD, USA
Funder
Intramural Research Program of the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health
Publisher
Informa UK Limited
Subject
Immunology,Immunology and Allergy
Link
https://www.tandfonline.com/doi/pdf/10.1080/1744666X.2020.1804362
Reference133 articles.
1. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
2. PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
3. Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
4. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
5. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Cited by 12 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Efficacy and safety of culture-expanded mesenchymal stromal cell therapy in the treatment of 4 types of inflammatory arthritis: A systematic review and meta-analysis of 36 randomized controlled trials;Seminars in Arthritis and Rheumatism;2024-10
2. The Utility of Laboratory Investigations for the Assessment and Management of Rheumatic Immune Related Adverse Events;Rheumatic Disease Clinics of North America;2024-05
3. Immune Checkpoint Inhibitor-induced Inflammatory Arthritis;Rheumatic Disease Clinics of North America;2024-05
4. Knowledge domains and emerging trends in immune-related adverse events from immune checkpoint inhibitors: A bibliometrics and visualized analysis;Heliyon;2024-03
5. Uncovering the flip side of immune checkpoint inhibitors: a comprehensive review of immune-related adverse events and predictive biomarkers;International Journal of Biological Sciences;2024
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3